The Mills-Peninsula Health Services Diabetes Research Institute in San Mateo, California, was the lead site and David C. Klonoff, M.D., was study chair of a national, multicenter study called ASPIRE (Automation to Simulate Pancreatic Insulin REsponse), an in-home clinical trial of the integrated MiniMed insulin pump with automatic insulin suspension, a feature called Threshold Suspend which is unique to MiniMed insulin pump systems. The trial was conducted at multiple investigational centers across the United States to determine the safety and efficacy of Threshold Suspend.
This clinical trial is the first, large in-home study to show the results of the integrated system when Threshold Suspend is incorporated. The trial compared two MiniMed sensor-augmented insulin pumps (integrated insulin pump with continuous glucose monitoring): one with the Threshold Suspend feature and one without.
In April 2013, nearly 200 scientists and clinicians from all over the world attended a conference called “Workshop on Innovation toward an Artificial Pancreas.” Among the physician researchers was David C. Klonoff, M.D., FACP, Fellow AIMBE, medical director of Mills-Peninsula’s Diabetes Research Institute.
New information on the current status of the artificial pancreas and the latest enabling technologies to advance this field was presented at the meeting. The purpose of the two-day conference was to have a multi-disciplinary discussion of advances and prospective areas of research that would accelerate the development and delivery of a wearable, automated artificial pancreas for individuals with diabetes.
Dr. Klonoff, was on the planning committee of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) / U.S. Food and Drug Administration, and chaired a session on “New Developments in Modeling, Algorithms and Technology. He also spoke at the meeting on the topic of mHealth (mobile health), delivering health care via mobile devices such as smartphones and wearable body sensors.
Great advances have occurred in diabetes research over the past decade, often in incremental steps, some which were taken at Mills-Peninsula’s Dorothy L. and James E. Frank Diabetes Research Institute in San Mateo, California.
“Diabetes is one of the most serious health problems of our time,” says David Klonoff, M.D., medical director of the Diabetes Research Institute (DRI) at Mills-Peninsula Health Services. “We conduct research to tackle this problem and work toward breakthroughs in care.”
Throughout 2012, the DRI conducted research studies, participated in hospital initiatives for diabetes care and performed service for Mills-Peninsula, the U.S. government, and the national and international scientific communities. In January, Dr. Klonoff compiled a summary of the DRI’s 12 grants for research conducted in 2012.
David C. Klonoff, M.D., FACP, medical director of the Diabetes Research Institute at Mills-Peninsula Health Services, has been elected a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). He will be inducted at the Fellow Induction and Awards Ceremony at AIMBE’s 22nd annual event in February, 2013 in Washington, D.C.
Being named a Fellow is considered one of the highest honors in the biomedical engineering discipline. Fellows represent the top two percent of the medical and biological engineering community.
AIMBE Fellows are leaders in bioengineering who are working to realize the institute’s vision to provide medical and biological engineering innovation for the benefit of humanity. The AIMBE College of Fellows consists of 1,000 individuals who are the outstanding bioengineers in academia, industry and government. These leaders in the field have distinguished themselves through their contributions in research, industrial practice and/or education.
“The mission of AIMBE is to promote public policies to foster advancement in medical and biological engineering,” Dr. Klonoff said. “At the Mills-Peninsula Diabetes Research Institute, we are applying advances in medical and bioengineering to develop new products to help people with diabetes. This award will help call attention to our hospital’s efforts to develop novel engineered devices, drug delivery systems and new medications that are safe and effective in the fight against diabetes, which is the world’s greatest epidemic.”
About Dr. David Klonoff
Dr. David Klonoff founded the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Health Services to facilitate development of new devices and drugs for people with diabetes. He is also a Clinical Professor of Medicine at the University of California, San Francisco (UCSF). Dr. Klonoff’s productivity includes 160 publications, two patents, and 86 clinical trials as principle investigator. Dr. Klonoff chaired the scientific advisory board for developing the first FDA-approved insulin patch pump and participated in development of the first FDA-approved dedicated diabetes telemedicine system, the first FDA-approved inhaled insulin, and the first three FDA-approved incretin drugs for diabetes. He is currently the lead investigator for the first-ever randomized controlled multicenter trial of the world’s first artificial pancreas product for outpatient use. Dr. Klonoff has chaired or served on 34 government grant review panels related to diabetes technology, including panels for National Institutes of Health, the Centers for Disease Control and Prevention, NASA, National Science Foundation, U.S. Army, JDRF, and the University of Michigan.
Diabetes researchers are closer than ever to creating an artificial pancreas, something that the Mills-Peninsula Diabetes Research Institute is currently working on. Nature, an international weekly journal of science news , published a story entitled “Medical devices: Managed by Machine” about this cutting-edge work in its May 16 issue.
The article reports on the promise of artificial pancreases in the management of type 1 diabetes and quotes David Klonoff, M.D., an endocrinologist and the medical director of the Diabetes Research Institute at Mills-Peninsula Health Services in San Mateo, Calif.
According to Nature, the U.S. Food and Drug Administration (FDA) identified the artificial pancreas as a top priority and, together with the U.S. National Institutes of Health (NIH), formed the Interagency Artificial Pancreas Working Group to identify and work through any clinical and scientific challenges. Meanwhile, government funding bodies in the United States and Europe, as well as many medical device companies, started spending tens of millions of dollars to encourage the development of an artificial pancreas.
Dr. Klonoff has been an advisor to the FDA while this agency has been developing policies for regulating this complicated device, and an advisor to the Juvenile Diabetes Research Foundation, which raises funds to support research for this technology. Dr. Klonoff was one of 150 scientists and clinicians recently asked by the NIH to contribute to the agency’s 10-year diabetes strategic planning report to identify where to allocate scientific expertise, tools, technologies and shared resources over the next decade – including aiming for the development of an artificial pancreas. Read More about Artificial Pancreas Being Tested by Mills-Peninsula Diabetes Expert